Kumar Sunil, Ng Jennifer, Gow Peter
Department of Medicine and Rheumatology, Middlemore Hospital, Otahuhu, South Auckland.
N Z Med J. 2005 Jun 24;118(1217):U1528.
To assess the efficacy and safety of benzbromarone in patients with renal impairment and severe tophaceous gout (despite receiving optimal conventional therapy).
Six patients with refractory gout (despite optimal therapy) were treated with benzbromarone. Uric acid levels and number of gout attacks were recorded monthly. Adverse events to medications were also recorded.
After 1 year of treatment with benzbromarone, average uric acid level reduced from 0.61 mmol/L to 0.46 mmol/L. Repeated measures tests on the changes in uric acid were clinically significant (p=0.01). The frequency of acute attacks of gout was reduced from 16 (8-20) to 7.3 (1-16); p=0.01. None of the patients reported adverse events with the medications. There were no acute flares resulting from initiation of medications.
Benzbromarone is effective in lowering uric acid levels and in reducing the number of acute attacks of gout in patients who have failed optimal treatment. Making this drug more readily available will increase our therapeutic choices for urate reduction and help decrease the morbidity associated with gout.
评估苯溴马隆对肾功能不全及重度痛风石性痛风患者（尽管接受了最佳常规治疗）的疗效和安全性。
对6例难治性痛风患者（尽管接受了最佳治疗）使用苯溴马隆进行治疗。每月记录尿酸水平和痛风发作次数。同时记录药物不良反应事件。
使用苯溴马隆治疗1年后，平均尿酸水平从0.61 mmol/L降至0.46 mmol/L。对尿酸变化进行的重复测量检验具有临床显著性（p = 0.01）。痛风急性发作频率从16次（8 - 20次）降至7.3次（1 - 16次）；p = 0.01。所有患者均未报告药物不良反应事件。未因开始用药而出现急性发作加剧情况。
对于接受最佳治疗仍无效的患者，苯溴马隆在降低尿酸水平及减少痛风急性发作次数方面有效。使这种药物更容易获得将增加我们降低尿酸的治疗选择，并有助于降低痛风相关的发病率。
